IL15 and rheumatoid arthritis: The first study by Rullmann, published in 2005, describes the application of the Entelos® (80) RA PhysioLab® platform to validate potential biological targets as well as to predict the effect of hypothetical anti-IL-15 and anti-IL-12 treatments on synovial cell density and cartilage degradation rate (30).